Krzysztof Brzozka

Company: Ryvu Therapeutics

Job title: Chief Scientific Officer & Executive Vice President

Seminars:

ONCO Prime – A Comprehensive Platform for Identification of KRAS-Specific Synthetic Lethal Targets Using Patient-Derived Cells 4:45 pm

• Showcasing Ryvu’s cutting-edge drug discovery platform, uniquely combining high throughput capabilities with the precision and translational impact traditionally associated with later, lower throughput stages • Leveraging human stem cell-derived model cells (PDC), patient-derived xenografts (PDXs) and clinical samples to create a groundbreaking approach to identify synthetic lethal (SL) targets specific to oncogenic pathways •…Read more

day: Day One